Menu

Vertex Pharmaceuticals

NASDAQ: VRTX

Vertex Pharmaceuticals is a biotechnology company that develops and commercializes medicines for serious diseases. Its core business focuses on cystic fibrosis treatments, with additional products for sickle cell disease, beta thalassemia and acute pain. Its expanding portfolio and drug development pipeline are key areas analysts evaluate.

Sector
Health Technology
Industry
Pharmaceuticals: Major
Employees
6,400
Founded
1989

The forecast figures are tipranks’s, read on 2026-10-26 and linked below.
The company facts and financials are CNN Business’s, read on 2026-11-16 and linked below.

Vertex Pharmaceuticals forecast

The forecast in short

tipranks records 24 analyst ratings on Vertex Pharmaceuticals and summarises them as “Strong Buy”. Their average 12-month price target is USD 589.45 (Potential Growth = 12.51%). Its tipranks score is 8 out of 10 — Outperform. These are tipranks’s figures as read on 2026-10-26, not CariBroker’s own view, and nothing here is advice to buy or sell.

Market cap

USD 136.01 B

≈ RM 556.36 B

Share price

USD 536.45

≈ RM 2194.40 · 18 Nov close

#163World ranking

tipranks score

Outperform

8

Analyst ratings

Strong Buy

  • Buy2188%
  • Hold313%
  • Sell00%

tipranks’s own summary of the 24 ratings above.

12 months price forecast

USD 589.45 Potential Growth = 12.51%

USD 398.19USD 495.94USD 593.69USD 691.44Past 12 months12 months forecastHighUSD 667AverageUSD 589.45LowUSD 4422025-102026-10

As tipranks publishes it. CariBroker has not recalculated any of it.

Financials

Q3 earnings, quarter ending Sep 29, 2026

MeasureQ3 20261-year change
Total revenue3.44B6.57% up
Net income653.60M45.13% down
Earnings per share2.5639.08% down
Net profit margin19.01%45.32% down
Free cash flow545.80M56.57% up
Debt-to-equity ratio0.31192.48% up

Revenue and net income, last 4 quarters

$0.0$1.0B$2.0B$3.0B$4.0BQ4 2025Q1 2026Q2 2026Q3 2026

Total revenueNet income

Analyst profiles: who made each call, and when

AnalystFromPositionTarget priceDated
Michael YeeUBSBuyUSD 6152026-10-24
Geoff MeachamCitiBuyUSD 5852026-10-19
Tazeen AhmadBank of America SecuritiesBuyUSD 6672026-10-16
Mohit BansalWells FargoBuyUSD 5502026-10-15
Evan SeigermanBMO CapitalBuyUSD 6002026-10-12
Show all 30
AnalystFromPositionTarget priceDated
Brian AbrahamsRBC CapitalBuyUSD 5762026-10-08
Terence FlynnMorgan StanleyBuyUSD 6652026-10-07
Jeffrey WalchBernsteinBuyUSD 6082026-09-25
Eliana MerleBarclaysBuyUSD 6172026-09-23
Danielle BrillTruist FinancialBuyN/A2026-09-23
Whitney IjemCanaccord GenuityHoldUSD 4422026-09-23
Louise ChenScotiabankBuyUSD 5582026-09-23
Akash TewariJefferiesBuyUSD 6402026-09-23
Paul MatteisStifel NicolausHoldN/A2026-09-22
Salveen RichterGoldman SachsBuyUSD 6532026-09-22
Andrew FeinH.C. WainwrightBuyUSD 6412026-09-22
Myles MinterWilliam BlairBuyN/A2026-09-22
Jessica FyeJ.P. MorganBuyUSD 5602026-09-11
Naz RahmanMaxim GroupBuyUSD 5752026-08-05
Phil NadeauTD CowenBuyUSD 5502026-08-04
Carter GouldCantor FitzgeraldBuyUSD 5952026-08-04
Joseph StringerNeedhamHoldN/A2026-08-04
Cory KasimovEvercore ISIBuyUSD 5352026-08-04
Andy ChenWolfe ResearchBuyUSD 5572026-08-03
Brian SkorneyRobert W. BairdSellUSD 3502026-07-07
Unknown AnalystRaymond JamesHoldN/A2026-06-24
Unknown AnalystGuggenheimBuyUSD 5462026-06-02
Hans EngelErste GroupHoldN/A2026-05-05
Nico ChenDBSBuyUSD 5402026-01-19
David RisingerLeerink PartnersBuyUSD 5252025-12-29

Investment strengths

High-quality profitability and cash generation

Vertex combines substantial revenue with unusually strong margins and cash conversion, giving it internal funding capacity for research, launches and business development. This financial strength can support investment through development cycles while reducing reliance on external financing over the next several quarters.

Durable cystic fibrosis franchise growth

The CF franchise continues to expand through uptake of ALYFTREK, supporting recurring demand from patients using chronic therapies. Growth in the established franchise provides a durable commercial base and creates resources to fund Vertex’s newer launches and pipeline programs.

Pipeline diversification and launch execution

Progress across cell therapy, pain, renal disease and other clinical programs reduces reliance on a single future product while broadening Vertex’s potential commercial base. Continued launches and advancing studies create multiple avenues for growth beyond its historical CF concentration.

People also ask

What is the 12-month price target for Vertex Pharmaceuticals (VRTX)?

tipranks publishes an average 12-month price target of USD 589.45 (Potential Growth = 12.51%), as read on 2026-10-26. The highest target is USD 667 and the lowest is USD 442. A price target is an analyst’s estimate of where a share might trade, not a promise, and CariBroker gives no investment advice.

See tipranks’s own page ↗

How many analysts cover Vertex Pharmaceuticals (VRTX)?

tipranks records 24 analyst ratings: 21 buy, 3 hold and 0 sell, which it summarises as “Strong Buy”, as read on 2026-10-26.

See tipranks’s own page ↗

What is the tipranks score for Vertex Pharmaceuticals (VRTX)?

tipranks scores it 8 out of 10 and calls that “Outperform”, as read on 2026-10-26. The score is tipranks’s, not CariBroker’s, and CariBroker does not rate listed shares.

See tipranks’s own page ↗

Is this CariBroker’s own forecast for Vertex Pharmaceuticals?

No. Every figure on this page is published by tipranks, copied on 2026-10-26 with a link to the original, and not recalculated. CariBroker checks financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.

See tipranks’s own page ↗

Disclaimer

CariBroker provides information only and does not provide investment, financial or legal advice.

All investment ideas

Check another company

Search every bank, broker and alert list in one place